IMMX vs LYRA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IMMX Captures Institutional Edge (2โ1 Pillars ยท 7โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immix Biopharma, Inc. Common Stock (IMMX) driven by superior Growth & Margin, Momentum & Technical while LYRA counters with relative strength in Options & Structure. Fundamentally, IMMX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus LYRA at N/M Forward P/E and -25032.0% operating margin (-87.2% YoY). In options structure, IMMX sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IMMX | LYRA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $657.1M | $2.3M | Larger Scale | IMMX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -87.2% | Higher Growth | IMMX |
| Operating Margin (TTM) Profitability | 0.0% | -25032.0% | Higher Margin | IMMX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -27.0% | -404.5% | Higher ROE | IMMX |
| 52-Week Range Position Momentum | 32% ($4โ$15) | 1% ($0โ$38) | Stronger Trend | IMMX |
| Beta / 30D Volatility Risk Regime | 1.83ฮฒ ยท 83% Vol | 0.33ฮฒ ยท 248% Vol | Lower Realized Risk | IMMX |
| Unified Institutional Score Composite Signal | 53.1 / 100 (HOLD) | 52.2 / 100 (HOLD) | Higher Composite | IMMX |